DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations
- Autores
- Abba, Martín Carlos; Zhong, Yi; Lee, Jaeho; Kil, Hyunsuk; Lu, Yue; Takata, Yoko; Simper, Melissa S.; Gaddis, Sally; Shen, Jianjun; Aldaz, C. Marcelo
- Año de publicación
- 2016
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Controversy always existed on the utility of chemically induced mouse mammary carcinogenesis models as valid equivalents for the study of human breast cancer. Here, we performed whole exome and RNA sequencing on long latency mammary tumors (218 ± 27 days) induced by the carcinogen 7,12-Dimethylbenzathracene (DMBA) and short latency tumors (65 ± 11 days) induced by the progestin Medroxyprogesterone Acetate (MPA) plus DMBA in CD2F1 mice. Long latency tumors displayed a high frequency of Pi3kca and/or Pten mutations detected in 11 of 13 (85%) long latency cases (14/22, 64% overall). Eighty-two percent (9/11) of tumors carried the Pik3ca H1047L/R hot-spot mutation, as frequently found in human breast cancer. These tumors were luminal-like and mostly ER/PR+, as in humans. Transcriptome profiling indicated a significant activation of the PI3K-Akt pathway (p=3.82e-6). On the other hand MPA+DMBA induced short latency tumors displayed mutations in cancer drivers not commonly found mutated in human breast cancer (e.g. Hras and Apc). These tumors were mostly basal-like and MPA exposure led to Rankl overexpression (60 fold induction) and immunosuppressive gene expression signatures. In summary, long latency DMBA induced mouse mammary tumors reproduce the molecular profile of human luminal breast carcinomas representing an excellent preclinical model for the testing of PIK3CA/Akt/mTOR pathway inhibitory therapies and a good platform for the developing of additional preclinical tools such as syngeneic transplants in immunocompetent hosts.
- Materia
-
Ciencias Médicas
mammary tumors
DMBA
MPA
Pik3ca
Pten - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- http://creativecommons.org/licenses/by/4.0/
- Repositorio
.jpg)
- Institución
- Comisión de Investigaciones Científicas de la Provincia de Buenos Aires
- OAI Identificador
- oai:digital.cic.gba.gob.ar:11746/6168
Ver los metadatos del registro completo
| id |
CICBA_a0e0557412fd16ec0451d2970e9abcee |
|---|---|
| oai_identifier_str |
oai:digital.cic.gba.gob.ar:11746/6168 |
| network_acronym_str |
CICBA |
| repository_id_str |
9441 |
| network_name_str |
CIC Digital (CICBA) |
| spelling |
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutationsAbba, Martín CarlosZhong, YiLee, JaehoKil, HyunsukLu, YueTakata, YokoSimper, Melissa S.Gaddis, SallyShen, JianjunAldaz, C. MarceloCiencias Médicasmammary tumorsDMBAMPAPik3caPtenControversy always existed on the utility of chemically induced mouse mammary carcinogenesis models as valid equivalents for the study of human breast cancer. Here, we performed whole exome and RNA sequencing on long latency mammary tumors (218 ± 27 days) induced by the carcinogen 7,12-Dimethylbenzathracene (DMBA) and short latency tumors (65 ± 11 days) induced by the progestin Medroxyprogesterone Acetate (MPA) plus DMBA in CD2F1 mice. Long latency tumors displayed a high frequency of <em>Pi3kca</em> and/or <em>Pten</em> mutations detected in 11 of 13 (85%) long latency cases (14/22, 64% overall). Eighty-two percent (9/11) of tumors carried the <em>Pik3ca</em> H1047L/R hot-spot mutation, as frequently found in human breast cancer. These tumors were luminal-like and mostly ER/PR+, as in humans. Transcriptome profiling indicated a significant activation of the PI3K-Akt pathway (p=3.82e-6). On the other hand MPA+DMBA induced short latency tumors displayed mutations in cancer drivers not commonly found mutated in human breast cancer (e.g. <em>Hras</em> and <em>Apc</em>). These tumors were mostly basal-like and MPA exposure led to <em>Rankl</em> overexpression (60 fold induction) and immunosuppressive gene expression signatures. In summary, long latency DMBA induced mouse mammary tumors reproduce the molecular profile of human luminal breast carcinomas representing an excellent preclinical model for the testing of PIK3CA/Akt/mTOR pathway inhibitory therapies and a good platform for the developing of additional preclinical tools such as syngeneic transplants in immunocompetent hosts.Impact Journals2016-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://digital.cic.gba.gob.ar/handle/11746/6168enginfo:eu-repo/semantics/altIdentifier/doi/10.18632/oncotarget.11733info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/reponame:CIC Digital (CICBA)instname:Comisión de Investigaciones Científicas de la Provincia de Buenos Airesinstacron:CICBA2025-11-27T08:33:36Zoai:digital.cic.gba.gob.ar:11746/6168Institucionalhttp://digital.cic.gba.gob.arOrganismo científico-tecnológicoNo correspondehttp://digital.cic.gba.gob.ar/oai/snrdmarisa.degiusti@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:94412025-11-27 08:33:37.292CIC Digital (CICBA) - Comisión de Investigaciones Científicas de la Provincia de Buenos Airesfalse |
| dc.title.none.fl_str_mv |
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations |
| title |
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations |
| spellingShingle |
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations Abba, Martín Carlos Ciencias Médicas mammary tumors DMBA MPA Pik3ca Pten |
| title_short |
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations |
| title_full |
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations |
| title_fullStr |
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations |
| title_full_unstemmed |
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations |
| title_sort |
DMBA induced mouse mammary tumors display high incidence of activating Pik3caH1047 and loss of function Pten mutations |
| dc.creator.none.fl_str_mv |
Abba, Martín Carlos Zhong, Yi Lee, Jaeho Kil, Hyunsuk Lu, Yue Takata, Yoko Simper, Melissa S. Gaddis, Sally Shen, Jianjun Aldaz, C. Marcelo |
| author |
Abba, Martín Carlos |
| author_facet |
Abba, Martín Carlos Zhong, Yi Lee, Jaeho Kil, Hyunsuk Lu, Yue Takata, Yoko Simper, Melissa S. Gaddis, Sally Shen, Jianjun Aldaz, C. Marcelo |
| author_role |
author |
| author2 |
Zhong, Yi Lee, Jaeho Kil, Hyunsuk Lu, Yue Takata, Yoko Simper, Melissa S. Gaddis, Sally Shen, Jianjun Aldaz, C. Marcelo |
| author2_role |
author author author author author author author author author |
| dc.subject.none.fl_str_mv |
Ciencias Médicas mammary tumors DMBA MPA Pik3ca Pten |
| topic |
Ciencias Médicas mammary tumors DMBA MPA Pik3ca Pten |
| dc.description.none.fl_txt_mv |
Controversy always existed on the utility of chemically induced mouse mammary carcinogenesis models as valid equivalents for the study of human breast cancer. Here, we performed whole exome and RNA sequencing on long latency mammary tumors (218 ± 27 days) induced by the carcinogen 7,12-Dimethylbenzathracene (DMBA) and short latency tumors (65 ± 11 days) induced by the progestin Medroxyprogesterone Acetate (MPA) plus DMBA in CD2F1 mice. Long latency tumors displayed a high frequency of <em>Pi3kca</em> and/or <em>Pten</em> mutations detected in 11 of 13 (85%) long latency cases (14/22, 64% overall). Eighty-two percent (9/11) of tumors carried the <em>Pik3ca</em> H1047L/R hot-spot mutation, as frequently found in human breast cancer. These tumors were luminal-like and mostly ER/PR+, as in humans. Transcriptome profiling indicated a significant activation of the PI3K-Akt pathway (p=3.82e-6). On the other hand MPA+DMBA induced short latency tumors displayed mutations in cancer drivers not commonly found mutated in human breast cancer (e.g. <em>Hras</em> and <em>Apc</em>). These tumors were mostly basal-like and MPA exposure led to <em>Rankl</em> overexpression (60 fold induction) and immunosuppressive gene expression signatures. In summary, long latency DMBA induced mouse mammary tumors reproduce the molecular profile of human luminal breast carcinomas representing an excellent preclinical model for the testing of PIK3CA/Akt/mTOR pathway inhibitory therapies and a good platform for the developing of additional preclinical tools such as syngeneic transplants in immunocompetent hosts. |
| description |
Controversy always existed on the utility of chemically induced mouse mammary carcinogenesis models as valid equivalents for the study of human breast cancer. Here, we performed whole exome and RNA sequencing on long latency mammary tumors (218 ± 27 days) induced by the carcinogen 7,12-Dimethylbenzathracene (DMBA) and short latency tumors (65 ± 11 days) induced by the progestin Medroxyprogesterone Acetate (MPA) plus DMBA in CD2F1 mice. Long latency tumors displayed a high frequency of <em>Pi3kca</em> and/or <em>Pten</em> mutations detected in 11 of 13 (85%) long latency cases (14/22, 64% overall). Eighty-two percent (9/11) of tumors carried the <em>Pik3ca</em> H1047L/R hot-spot mutation, as frequently found in human breast cancer. These tumors were luminal-like and mostly ER/PR+, as in humans. Transcriptome profiling indicated a significant activation of the PI3K-Akt pathway (p=3.82e-6). On the other hand MPA+DMBA induced short latency tumors displayed mutations in cancer drivers not commonly found mutated in human breast cancer (e.g. <em>Hras</em> and <em>Apc</em>). These tumors were mostly basal-like and MPA exposure led to <em>Rankl</em> overexpression (60 fold induction) and immunosuppressive gene expression signatures. In summary, long latency DMBA induced mouse mammary tumors reproduce the molecular profile of human luminal breast carcinomas representing an excellent preclinical model for the testing of PIK3CA/Akt/mTOR pathway inhibitory therapies and a good platform for the developing of additional preclinical tools such as syngeneic transplants in immunocompetent hosts. |
| publishDate |
2016 |
| dc.date.none.fl_str_mv |
2016-08 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://digital.cic.gba.gob.ar/handle/11746/6168 |
| url |
https://digital.cic.gba.gob.ar/handle/11746/6168 |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.18632/oncotarget.11733 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by/4.0/ |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Impact Journals |
| publisher.none.fl_str_mv |
Impact Journals |
| dc.source.none.fl_str_mv |
reponame:CIC Digital (CICBA) instname:Comisión de Investigaciones Científicas de la Provincia de Buenos Aires instacron:CICBA |
| reponame_str |
CIC Digital (CICBA) |
| collection |
CIC Digital (CICBA) |
| instname_str |
Comisión de Investigaciones Científicas de la Provincia de Buenos Aires |
| instacron_str |
CICBA |
| institution |
CICBA |
| repository.name.fl_str_mv |
CIC Digital (CICBA) - Comisión de Investigaciones Científicas de la Provincia de Buenos Aires |
| repository.mail.fl_str_mv |
marisa.degiusti@sedici.unlp.edu.ar |
| _version_ |
1849948605231661057 |
| score |
13.011256 |